Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating activities:
Net loss	$ (48,697,000)	$ (24,396,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,300,000	7,395,000
Goodwill impairment charge	23,989,000	0
Non-cash lease expense	(304,000)	(191,000)
Non-cash transaction costs including amortization of debt discount and issuance costs	0	5,993,000
Change in fair value of warrant and derivative liabilities	(372,000)	(4,214,000)
Loss on derecognition of debt	0	3,991,000
Stock based compensation	4,503,000	4,835,000
Deferred income taxes	(40,000)	(10,000)
Gain on license of patents, net	(198,000)	0
Loss on disposal of assets	0	12,000
Changes in operating accounts:
Accounts receivable	2,191,000	2,589,000
Prepaid expenses and other assets	361,000	12,000
Accounts payable and accrued liabilities	(1,934,000)	(2,825,000)
Other liabilities	(94,000)	(164,000)
Net cash used in operating activities	(14,295,000)	(6,973,000)
Investing activities:
Capital expenditures, net	(20,000)	(4,000)
Proceeds from license of patents, net	198,000	0
Other investing activities, net	0	136,000
Net cash provided by investing activities	178,000	132,000
Financing activities:
Proceeds from Common Stock, Private Placement, Warrants, Pre-Funded Warrants Offerings, net	9,839,000	0
Proceeds from financing arrangements	1,043,000	981,000
Repayments of financing arrangements	(1,087,000)	(1,036,000)
Other financing activities	5,000	(5,000)
Net cash provided by (used in) financing activities	9,800,000	(60,000)
Net decrease in cash and cash equivalents	(4,317,000)	(6,901,000)
Cash and cash equivalents, beginning of period	7,125,000	14,026,000
Cash and cash equivalents, end of period	2,808,000	7,125,000
Supplemental disclosures of cash flow information:
Cash paid for income taxes	0	187,000
Non-cash investing and financing activities:
Issuance of common stock in settlement and prepayment of notes payable	$ 0	$ 15,000,000